Researchers publish consensus statement on patient selection and appropriate use of Lu-177 PSMA-617 radionuclide therapy

by

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177Lu-PSMA radionuclide therapy.

Leave A Comment

Your email address will not be published. Required fields are marked *